Skip to main content
SpringerLink
Log in

Identifying new Risk Markers and Potential Targets for Coronary Artery Disease: The Value of the Lipidome and Metabolome

  • ORIGINAL ARTICLE
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Purpose

This systematic review was performed to summarize published data on lipidomic and metabolomic risk markers of coronary artery disease.

Methods

Studies were identified from a literature search of PubMed.

Results

Published data shows that analysis of metabolites and lipids offers an opportunity to increase our knowledge of the biological processes related to development and progression of atherosclerotic coronary disease. It is evident that advanced analytical technologies are able to detect and identify a large number of molecules that may have important structural and functional roles over and above currently used biomarkers in the cardiovascular field. It is suggested in a number of reports that the novel biomarkers can be used to improve risk stratification and patient selection for different treatments. Also, monitoring treatment efficacy and safety as well as lifestyle changes should be facilitated by such novel markers.

Conclusion

Until now a plethora of biomarker candidates associated with cardiovascular event risk have been identified, but very few have passed through clinical and analytical validation and found their way into clinical use. Consequently, the appetite of physicians to use these novel tests in daily clinical routine has not yet been truly tested.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Heiskanen LA, Suoniemi M, HX T, Tarasov K, Ekroos K. Long-term performance and stability of molecular shotgun lipidomic analysis of human plasma samples. Anal Chem. 2013;85:8757–63.

    Article  CAS  PubMed  Google Scholar 

  2. Morris M, Watkins SM. Focused metabolomic profiling in the drug development process: advances from lipid profiling. Curr Opin Chem Biol. 2005;9:407–12.

    Article  CAS  PubMed  Google Scholar 

  3. Ganna A, Salihovic S, Sundström J, Broeckling CD, Hedman ÅK, Magnusson PKE, et al. Large-scale metabolomic profiling identifies novel biomarkers for incident coronary heart disease. PLoS Genet. 2014;10:e1004801.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Vaarhorst AAM, Verhoeven A, Weller CM, Böhringer S, Göraler S, Meissner A, et al. A metabolomic profile is associated with the risk of incident coronary heart disease. Am Heart J. 2014;168:45–52.

    Article  CAS  PubMed  Google Scholar 

  5. Henneman P, Aulchenko YS, Frants RR, van Dijk KW, Oostra BA, van Duijn CM. Prevalence and heritability of the metabolic syndrome and its individual components in a Dutch isolate: the erasmus rucphen family study. J Med Genet. 2008;45:572–7.

    Article  CAS  PubMed  Google Scholar 

  6. Wurtz P, Havulinna AS, Soininen P, Tynkkynen T, Prieto-Merino D, Tillin T, et al. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation. 2015;131:774–85.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Tillin T, Hughes AD, Mayet J, Whincup P, Sattar N, Forouhi NG, et al. The relationship between metabolic risk factors and incident cardiovascular disease in Europeans, south Asians, and African caribbeans. J Am Coll Cardiol. 2013;61:1777–86.

    Article  PubMed  PubMed Central  Google Scholar 

  8. May M, Lawlor DA, Brindle P, Patel R, Ebrahim S. Cardiovascular disease risk assessment in older women: can we improve on framingham? British women’s heart and health prospective cohort study. Heart. 2006;92:1396–401.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Shah SH, Sun J-L, Stevens RD, Bain JR, Muehlbauer MJ, Pieper KS, et al. Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. Am Heart J. 2012;163:844–50.

    Article  CAS  PubMed  Google Scholar 

  10. AA S, DM C, JK S, Haynes C, RC S, MJ M, et al. Metabolic profiles predict adverse events after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2012;143:873–8.

    Article  Google Scholar 

  11. Wang Z, Klipfell E, Bennett BJ, Koeth R, Bruce S, Dugar B, et al. Cardiovasc Dis. 2011;472:57–63.

    CAS  Google Scholar 

  12. Tang WHW, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368:1575–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wang Z, Tang WHW, JA B, X F, EB B, RA K, et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J. 2014;35:904–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Fernandez C, Sandin M, Sampaio JL, Almgren P, Narkiewicz K, Hoffmann M, et al. Plasma lipid composition and risk of developing cardiovascular disease. PLoS One. 2013;8:e71846.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Stegemann C, Pechlaner R, Willeit P, Langley SR, Mangino M, Mayr U, et al. Lipidomics profiling and risk of cardiovascular disease in the prospective population-based bruneck study. Circulation. 2014;129:1821–31.

    Article  CAS  PubMed  Google Scholar 

  16. Meikle PJ, Wong G, Tsorotes D, Barlow CK, Weir JM, Christopher MJ, et al. Plasma lipidomic analysis of stable and unstable coronary artery disease. Arterioscler Thromb Vasc Biol. 2011;31:2723–32.

    Article  CAS  PubMed  Google Scholar 

  17. Park JY, Lee S, Shin M, Hwang G. Alteration in metabolic signature and lipid metabolism in patients with angina pectoris and myocardial infarction. PLoS One. 2015;10:e0135228.

  18. Winkelmann BR, Marz W, Boehm BO, Zotz R, Hager J, Hellstern P, et al. Rationale and design of the LURIC study–a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics. 2001;2:S1–73.

    Article  CAS  PubMed  Google Scholar 

  19. Tarasov K, Ekroos K, Suoniemi M, Kauhanen D, Sylvänne T, Hurme R, et al. Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency. J Clin Endocrinol Metab. 2014;99:E45–52.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Cheng JM, Suoniemi M, Kardys I, Vihervaara T, de Boer SPM, Akkerhuis KM, et al. Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: results of the ATHEROREMO-IVUS study. Atherosclerosis. 2015;243:560–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The author thanks Dr. Reini Hurme and associate professor Peter Meikle for their valuable comments. This work has received funding from the European Union’s Seventh Framework Programme FP7/2007-2013 under grant agreement n° 305739 (RiskyCAD).

Author information

Authors and Affiliations

  1. Zora Biosciences Oy, Biologinkuja 1, 02150, Espoo, FI, Finland

    Reijo Laaksonen

  2. Medical School, University of Tampere, Tampere, Finland

    Reijo Laaksonen

  3. Finnish Clinical Biobank, University Hospital of Tampere, Tampere, Finland

    Reijo Laaksonen

Authors
  1. Reijo Laaksonen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Reijo Laaksonen.

Ethics declarations

Conflict of Interest

Zora Biosciences holds patents for the diagnostic use of ceramides and Dr. Laaksonen is shareholder and employee of Zora Biosciences. The author has no other conflict of interest to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Laaksonen, R. Identifying new Risk Markers and Potential Targets for Coronary Artery Disease: The Value of the Lipidome and Metabolome. Cardiovasc Drugs Ther 30, 19–32 (2016). https://doi.org/10.1007/s10557-016-6651-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-016-6651-8

Keywords

Search

Navigation